Lisata Therapeutics Announces Outcome Of Interim Futility Analysis For Phase 2b ASCEND Trial Of LSTA1 In Metastatic Pancreatic Ductal Adenocarcinoma; Trial Will Continue As Planned Without Modification
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics announced that the interim futility analysis for the Phase 2b ASCEND trial of LSTA1 in metastatic pancreatic ductal adenocarcinoma will continue as planned without modification.
September 06, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The Phase 2b ASCEND trial of LSTA1 by Lisata Therapeutics will continue as planned, indicating positive preliminary results.
The continuation of the Phase 2b ASCEND trial of LSTA1 without modification indicates that the interim futility analysis did not find sufficient reason to halt or modify the trial. This suggests that the trial is showing promising preliminary results, which could potentially boost Lisata Therapeutics' stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100